Treatment of Bronchial Asthma(difficulty in breathing) with Unani medicine Habb-e-Banafsha
- Conditions
- Health Condition 1: J453- Mild persistent asthma
- Registration Number
- CTRI/2021/05/033781
- Lead Sponsor
- Central Council for Research in Unani Medicine CCRUM New Delhi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Subjects of either sex between the age group of 18-65 years.
2. Subjects of Bronchial Asthma for at least 6 months presenting with at least one of the following symptoms:
Wheeze
Shortness of breath
Chest tightness and cough that vary over
time and in intensity,
Expiratory airflow limitation as suggested
by a decreased FEV1
3. Objective evidence for reversible airway
obstruction (>=12% and >=200 mL change in FEV1
and/or a 25% and 60 L/min change in PEFR)
either spontaneously or after treatment.
4. Subjects with Asthma Control Questionnaire Score > 1.5
1. FEV1/FVC ratio < 50%
2. Pregnant and lactating females
3. Subjects with other Respiratory Tract Infections, tuberculosis and malignancy.
4. Subjects of Presence of chronic cough with expectoration for 2-3 months in each of two successive years.
5. Subjects with co-morbidities; Diabetes Mellitus, Hepatic and Renal Insufficiency
6. Subjects with known interstitial lung disease.
7. Subjects with Tobacco Smoking.
8. Subjects with known chronic obstructive pulmonary disease (COPD)
9. Patient with regular use of oral or systemic corticosteroids for conditions other than Asthma.
10. Subjects who are not willing to participate in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in signs and symptoms of Zeeq un-Nafas Rewi (Bronchial Asthma)Timepoint: 1 week
- Secondary Outcome Measures
Name Time Method Haematological and biochemical assessment for safety assessmentTimepoint: At baseline and after four weeks